A
Acariasis
African Horse
Sickness
African Swine
Fever
Aino Disease
Akabane
Amblyomma hebraeum
Amblyomma
variegatum
American Cattle
Tick
See:
Boophilus annulatus
Anthrax
Aujeszky`s Disease
Avian Influenza
Avian
Mycoplasmosis
B
Bartonellosis
See: Cat Scratch Disease
Baylisascariasis
Blue Eye Disease
Bluetongue
Boophilus
annulatus
Boophilus
microplus
Botulism
Bovine Babesiosis
Bovine Ephemeral
Fever
Bovine Spongiform
Encephalopathy
Bovine
Tuberculosis
Brown Ear Tick
See: Rhipicephalus appendiculatus
Brucella abortus
Brucella canis
Brucella
melitensis
Brucella ovis
Brucella suis
Brucellosis
Brucellosis
(Marine Mammals)
C
Camelpox
Campylobacteriosis
Canine Influenza
Caprine Arthritis
and Encephalitis
Castor Bean Tick
See: Ixodes ricinus
Cat Scratch
Disease
Cattle Fever
See: Bovine Babesiosis
Chagas
(Trypanosomiasis-American)
Chlamydiosis
(Avian)
Chlamydiosis
(Mammalian)
Cholera
Chronic Wasting
Disease
Classical Swine
Fever
Coccidioidomycosis
Coggins Disease
See: Equine Infectious Anemia
Contagious
Agalactia
Contagious Bovine
Pleuropneumonia
Contagious Caprine
Pleuropneumonia
Contagious Ecthyma
Contagious Equine
Metritis
Coxiellosis
See: Q Fever
Crimean-Congo
Hemorrhagic Fever
Cryptococcosis
Cryptosporidiosis
Cysticercosis
See: Taenia
D
Dermatophilosis
Dermatophytosis
Dourine
Duck Virus
Enteritis
Duck Virus
Hepatitis
E
Eastern Equine
Encephalomyelitis
Ebola Virus
Disease
Echinococcosis
Egg Drop Syndrome
Ehrlichiosis
Enterovirus
Encephalomyelitis
Epizootic
Hematopoietic Necrosis
Epizootic
Hemorrhagic Disease
Epizootic
Lymphangitis
Epsilon Toxin of
Clostridium perfringens
Equine Babesiosis
See: Equine Piroplasmosis
Equine Encephalitides
Equine Infectious
Anemia
Equine
Piroplasmosis
Equine Viral
Arteritis
Escherichia coli
0157:H7
Exotic Ticks
See: Ticks (Exotic)
Ivermectin Injection,Veterinary Injection,Veterinary Products,Veterinary Tablet NOUVASANT GROUP LTD. , https://www.nouvasant.com
China has developed molecular imaging medical devices with independent intellectual property rights
In the field of medical imaging, Detection Technology stands as a leading innovator in China, setting new benchmarks in high-end molecular imaging devices with independent intellectual property rights. For years, Chinese pharmaceutical researchers have faced challenges due to the lack of advanced molecular imaging equipment domestically, leaving a significant gap in this emerging sector. Most hospitals and research institutions in China rely heavily on imported medical imaging systems, particularly for large-scale equipment, which has long been a bottleneck for domestic scientific development.
To address these limitations, since 2003, Professor Tian Jie from the Chinese Academy of Sciences’ Institute of Automation led a team of nearly 50 master’s and doctoral students in researching and developing "medical imaging and molecular imaging" technology. In 2006, the Ministry of Science and Technology included the “Research on Key Scientific and Technological Issues of Molecular Imaging†in the National 973 Program, with Professor Tian Jie serving as the chief scientist.
So far, the project has achieved remarkable milestones. One key outcome is the successful commercialization of the molecular imaging system. In December, Guangzhou Zhongke Yusheng Medical Devices Co., Ltd. introduced an in-vivo autofluorescence molecular imaging system to the market, filling a critical gap in China's high-end medical device industry with indigenous technology.
According to the company's officials, while similar products exist internationally, Zhongke Yusheng’s system offers more comprehensive capabilities, enabling the detection of complex non-homogeneous biological structures such as the heart, liver, spleen, and lungs. The technology has reached or even surpassed international standards, while offering significantly lower costs compared to existing alternatives.
Early detection of birth path lesions is one of the most promising applications of the system. After its prototype was launched last year, the system underwent extensive improvements before being fully released to the market. It can now observe disease progression, especially cancerous lesions, and track responses to drug treatments. The system is also used in virology research, transgenic animal model development, stem cell studies, protein interaction analysis, and in vitro cell testing.
What makes the system stand out is its non-invasive nature. Unlike traditional methods like X-rays or CT scans that use radiation and may cause side effects, Zhongke Yusheng’s molecular imaging technology uses near-infrared fluorescence, ensuring no harm to the organism being tested. Additionally, it can detect diseases at earlier stages than conventional techniques. While current technologies can only identify tumor cells after they form, molecular imaging can detect cellular changes during the early stages of disease development, enabling true early diagnosis.
The system's applications extend beyond medicine into food safety testing, plant research, and pharmaceutical formulation. Zhongke Yusheng focuses on product development, drug evaluation, and testing, and the system offers superior cost-performance compared to similar products both domestically and internationally.
As a high-tech enterprise based in Guangzhou, Zhongke Yusheng has received strong government support, including a 5 million yuan special fund. The company has also partnered with Xidian University to establish the "Engineering Research Center of Biomedical Imaging," continuing to advance its work in molecular imaging.
Looking ahead, the company plans to build a robust service platform, enhance product promotion, and strive for both social and economic benefits. With a supportive policy environment and a growing demand for innovative medical technologies, Zhongke Yusheng is well-positioned to lead the future of molecular imaging in China.
...